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Abstract
While patient management in the intensive care unit has undoubtedly improved over the last 20 years, many questions
remain. Neurological prognostication has become very important and aided in improving survival outcomes over time. The
limited number of randomized control trials and limitations from currently completed studies leave the field with little certainty
regarding targeted temperature management. In addition, implementing hypothermia can use multiple methods and protocols
that impact the interpretation and comparison of results.
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Introduction
To improve survival after sudden cardiac arrest, the
American Heart Association published the concept of “the
chain of survival” as early as 1991.1 Peter Safar first used this
phrase to describe the coordinated effort to gain spontaneous
circulation by paramedics, emergency physicians, and
intensivists.2 As field care improved, the number of critically
ill patients requiring care in the intensive care unit (ICU) grew.
Currently, early mortality after resuscitation arises from the
underlying cardiogenic shock state and the precipitating cause
of cardiac arrest. Later mortality is largely caused by
neurological injury and end-organ damage as a sequela of
cardiac arrest.

Target Temperature Management
Early data from the Hypothermia After Cardiac Arrest
Study Group demonstrated a benefit from target temperature
management (TTM),3 which is a strategy of deliberate
temperature management with active cooling, rewarming, and
extended fever control. The recommendation for all adult
comatose patients with Glasgow Coma Scales less than 8 is to
undergo TTM to achieve temperatures between 32.0 and

36.0C. Cooling actively prevents pyrexia, which decreases
damage to the brain and other organs by lowering tissue
metabolism, reminiscent of limiting the infarct size in the
heart,
post-myocardial
infarction
by
attenuating
ischemia/reperfusion injury. The evidence to support this
recommendation stems from data indicating that fevers greater
than 37.7C are associated with a poor outcome. The worst
outcomes are associated with temperatures greater than
39.0C. Initial clinical trials with mild hyperthermia within 12
to 24 hours of care showed improved survival and
neurological outcomes after out-of-hospital cardiac arrest in
patients with shockable rhythms compared to usual care.3

Literature Review
Written guidelines strongly recommend the use of TTM
despite evidence with low certainty. In 2019, the results of an
open-label trial of 584 patients from 25 ICUs were published.4
Subjects experienced out-of-hospital cardiac arrest and were
randomized to TTM or usual care regardless of shockable
rhythm; the study failed to show the superiority of the use of
TTM.
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A more recent study from 2021 enrolled 1900 adults
without a hospital cardiac arrest who were randomized to
hypothermia with temperatures targeting 33C or
normothermia.5 The results of this randomized controlled trial
(RCT) showed that both the hypothermia and the
normothermia groups had a 50% mortality rate, and there was
no difference concerning functional outcomes at six months
for survival or neurological outcomes. Interestingly,
arrhythmias were more common in the hypothermia group (24
vs. 17%), but there was no difference in other prespecified
adverse events.5
A lot has changed in the last two decades regarding ICU
care; thus, it is not surprising that this study directly
contradicts the study published 20 years ago where the benefit
of hypothermia was reported. Further, the more recent trial has
several limitations, including the lack of a true control group.5
The intervention could not be blinded, which may have
influenced the outcomes. In addition, about 20% of subjects
were co-enrolled in another trial.5 A letter to the editor
commented on several concerns that mainly related to the
generalizability of the study.6 They noted that 75% of patients
had a shockable rhythm, and only 80% of patients had
received bystander cardiopulmonary resuscitation (CPR).6
With so much debate, a recent systematic review provides
key takeaways.7 Over 3400 articles from 2001 to 2020 were
screened, and 32 related trials were identified. Of note, only 9
trials compared normothermia and hypothermia (32 - 34C).
Most of the trials were small feasibility or pilot studies, with
only 3 trials having more than 100 patients enrolled. The
overall summary of this systematic review and meta-analysis
was that TTM does not clearly provide a benefit when
compared to normothermia, although the certainty of the
evidence was low.7
Veno-arterial extracorporeal membrane oxygenation (VA ECMO) has emerged as a viable therapy for cardiac arrest,
particularly in the setting of extracorporeal CPR (ECPR).
Studies are currently being conducted in France, the Czech
Republic, and Taiwan to assess outcomes of ECPR in out-ofhospital cardiac arrest. More importantly, there have also been
studies that considered V-A ECMO in an acute setting with
hypothermia.8 The 2022 Extracorporeal Life Saving
Organization Registry Report confirmed the survival to
hospital discharge in adults with ECPR is as low as 30%.
There is no further granularity concerning TTM in these
patients. In considering ECPR with hypothermia, one of the
first reports was from the CHEER Trial in 2015.8 This was a
single-center, feasibility trial that compared only 26 patients.
The authors concluded that hypothermia was associated with
higher survival than ECPR alone.8
Duan and colleagues completed a meta-analysis of
articles that evaluated CPR strategies for patients with cardiac
arrest. They analyzed 21 full-text articles from 2000 to 2020.9
Many of the studies enrolled patients who had out-of-hospital
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cardiac arrest, with most of these arrests being witnessed.
There was inconsistent use of bystander CPR, and
surprisingly, the time of initiation of cannulation ranged from
34 minutes to 185 minutes. More importantly, most of these
studies were retrospective in nature, and only five studies were
prospectively designed or included randomization and
controls. Sample sizes ranged from 600 to 231 patients. There
was a favorable rate of survival to hospital discharge over 28
days (odds ratio [OR] = 2.27) and better neurological
outcomes in the group that received hypothermia (OR > 2.0).
The benefit holds for survival outcomes at 3 months for both
survival and neurological outcomes.9
This year, Levy and colleagues from the ECMO Net
published the results of an RCT of early initiation of
hypothermia versus normothermia for 24 hours in patients
with cardiogenic shock supported with V-A ECMO.10 The
multi-site study in France collected data from 20 centers
between 2016 and 2019. They hypothesized that early
hypothermia improves survival rates of patients with
cardiogenic shock supported by V-A ECMO. A total of 374
patients were randomized, and they found that the
hypothermia group had a lower mortality rate when compared
to the normothermia group (42% versus 51%). However, this
was not statistically significant, with a P-value of only .07.10
Likewise, a single-center experience with patients on V-A
ECMO demonstrated improved neurological recovery with
TTM, but there was no association with improved mortality
with hypothermia.11

Conclusion
While patient management in the ICU has undoubtedly
improved over the last 20 years, many questions remain.
Neurological prognostication has become very important and
aided in improving survival outcomes over time. The limited
number of randomized control trials and limitations from
currently completed studies leave the field with little certainty
regarding
temperature
management.
In
addition,
implementing hypothermia can use multiple methods and
protocols that impact the interpretation and comparison of
results.
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